Are real-world outcomes matching LAA occluder trials

In my last two client reviews, 12-month real-world follow-up showed more peridevice leaks than the pivotal RCTs, while stroke rates remained comparable. Are you seeing similar signals in MAUDE and local registries over the past 6 months, and what event thresholds are you using to trigger CAPA or additional PMCF?

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍⁠‌‌‍‌‌‌‍‌​‌‍‍‌‌‍​⁠‌‍​‌‌‍⁠​‌⁠​⁠‌‍​‌‌‍⁠​‌‍‌‌‌⁠​⁠​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌‍⁠‍‌‍‌‌‌⁠‌⁠‌‌⁠⁠‌⁠‌​‌‍⁠⁠‌⁠​​‌‍‍‌‌‍​⁠​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​‍​‍‌‍⁠‍‌‍‌‌‌⁠‌⁠​‍​‍​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‌​⁠​‌​⁠​‍​⁠​‌​⁠‍​​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌‍​‌‌⁠‍‌‌‍‍‍‌​‌‌‌‍‌⁠​⁠​‍‌​‌​‌‌‍​‌‌‌‌​⁠‌‍‌‍‍​‌‍‍‍​⁠‌‍‌​‌​‌​⁠​​⁠‍‌​‍​‍‌⁠⁠‌​​